Company: SPRB
Filing Date: 2025-04-15
Form Type: 8-K
Source: 0000950170-25-053944
Chunk: 2

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-04-15
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit      Description                                                                                                                                                    
                                                                                                                                                                              
      No.                                                                                                                                                                     
     99.1      Press Release of Spruce Biosciences, Inc., dated April 15, 2025.                                                                                               
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
     99.2      Presentation of Spruce Biosciences, Inc. entitled “ Tralesinidase Alfa Enzyme Replacement Therapy for the Treatment of Sanfilippo Syndrome Type B (MPSIIIB).”  
      104      Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document                                                       

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Spruce Biosciences, Inc.                                             
  By:                           /s/ Samir Gharib                       
                                Samir Gharib                           
                                President and Chief Financial Officer